Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05370430 · ClinicalTrials.gov registry record · Phase 1
BAFFR-targeting CAR T Cells for Patients With Relapsed or Refractory B-NHL
A Phase 1 study of Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma, sponsored by PeproMene Bio.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 36
- Enrollment target
- 6
- Study locations
NCT05370430: Recruiting Phase 1 study of Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma, sponsored by PeproMene Bio.
NCT05370430 is a Phase 1 study of Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma that is actively recruiting participants, run by PeproMene Bio. The registered enrollment target is 36 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (40% lower). The trial reports 6 study locations across 5 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05370430, a Phase 1 study of Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma, is actively recruiting participants, sponsored by PeproMene Bio.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 36 participants
- Enrollment target
- 6
- Study locations
Study Summary
A Phase 1 Study Evaluating BAFFR-targeting CAR T Cells for Patients with Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma (B-NHL)
Primary Outcome
Assess the safety of administering BAFFR-CAR T cells in participants with relapsed or refractory (r/r) B-cell Non-Hodgkin's Lymphoma (B-NHL) and it's subtypes. Toxicity will be graded per Common Terminology Criteria for Adverse Events version 5.0, Cytokine Release Syndrome (CRS) and neurotoxicity which use the American Society for Transplantation and Cellular Therapy Consensus Criteria (ASTCT) and Graft versus Host Disease (GVHD) criteria. Toxicities will be followed from the start of lymphodepl
Conditions Studied
Interventions
- BIOLOGICAL BAFFR-CAR T cells
Study Locations (6)
California
- City of Hope Medical Center - Duarte
- Stanford University - Stanford
Kansas
- University of Kansas Hospital - Kansas City
Minnesota
- University of Minnesota - Minneapolis
North Carolina
- Atrium Health Levine Cancer Institute - Morehead - Charlotte
Washington
- Providence Swedish Cancer Institute - Seattle
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 36 participants |
| Start Date | 2022-06-13 |
| Est. Completion | 2028-06-13 |
| Phase | Phase 1 |
What NCT05370430 shows while recruiting
NCT05370430 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 36 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (40% lower).
The record links to 1 condition, with Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma appearing as the primary indexed condition, and to 1 intervention - of which BAFFR-CAR T cells is the first listed.
NCT05370430 lists 6 locations in 5 states (California, Kansas, Minnesota).
Frequently Asked Questions
What is clinical trial NCT05370430 about?
NCT05370430 is a clinical study titled "BAFFR-targeting CAR T Cells for Patients With Relapsed or Refractory B-NHL". A Phase 1 Study Evaluating BAFFR-targeting CAR T Cells for Patients with Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma (B-NHL)
What is the current status of trial NCT05370430?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 36 participants. The study started on 2022-06-13. Estimated completion is 2028-06-13.
What conditions does trial NCT05370430 study?
This clinical trial studies the following conditions: Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma.
What interventions are being tested in trial NCT05370430?
The interventions under investigation include: BAFFR-CAR T cells (BIOLOGICAL).
Who is sponsoring clinical trial NCT05370430?
This trial is sponsored by PeproMene Bio, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05370430 being conducted?
This trial has 6 study locations across California, Kansas, Minnesota, North Carolina, Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05370430's enrollment target sits among peer trials
36 1211th of 2000 higher than 743 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00929006 · 36 participants · Early Phase 1
Acute Progesterone Suppression of Wake vs. Sleep Luteinizing Hormone Pulse Frequency in Pubertal Girls With and Without Hyperandrogenism
- NCT01891318 · 36 participants · Phase 1
Neoadjuvant Radiosurgery for Resectable Brain Metastases: Phase I/II Study
- NCT02291848 · 36 participants · Phase 1
Tumor-Associated Antigen-Specific Cytotoxic T-Lymphocytes for Multiple Myeloma
- NCT02366819 · 36 participants · Phase 4
Genetic Analysis-Guided Irinotecan Hydrochloride Dosing of mFOLFIRINOX in Treating Patients With Locally Advanced Gastroesophageal or Stomach Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI